Looking for research-grade compounds?
Semax peptide research occupies an unusual place in the neuropeptide literature. Most research peptides have a thin publication record and no regulatory history anywhere in the world. Semax is the opposite in one respect and identical in another: it has been studied for more than four decades, it is a registered medicine in Russia, and it has a substantial body of work on brain-derived neurotrophic factor (BDNF), its receptor TrkB, and neuroprotection in ischemia models — yet it is not approved by the FDA or the EMA, the human evidence is concentrated in Russian-language journals, and in the United States it is supplied strictly as a research-use-only (RUO) laboratory material. This article works through what semax peptide research actually shows: where the molecule came from, how it is proposed to work, what the animal and human studies found, and where the evidence runs out.
Semax is a synthetic heptapeptide — seven amino acids — with the sequence Met-Glu-His-Phe-Pro-Gly-Pro (MEHFPGP). Its first four residues reproduce positions 4–7 of adrenocorticotropic hormone (ACTH), the pituitary hormone best known for driving cortisol release from the adrenal glands. The final three residues, Pro-Gly-Pro (PGP), are not part of ACTH at all. They were appended by the peptide’s designers as a stabilizing tail, because proline-rich C-terminal sequences resist the enzymes that normally break small peptides down within minutes.
That design solves a specific problem. Short ACTH fragments such as ACTH(4–10) had been known since the 1960s and 1970s to influence learning and memory processes in animal models, but they were degraded so quickly that they made poor research tools and poorer drug candidates. Semax was developed in the 1980s at the Institute of Molecular Genetics of the Russian Academy of Sciences, working with the Zakusov Institute of Pharmacology, specifically to keep the central nervous system activity associated with the ACTH fragment while removing two things: the steroidogenic (cortisol-raising) activity of full-length ACTH, and the fragility of the natural fragment.
The steroidogenic point matters for researchers. The part of ACTH that activates the adrenal MC2R receptor and triggers cortisol release sits in a different region of the molecule. Semax does not carry that activity, which is why the literature describes it as a melanocortin-derived neuropeptide analog without classic hormonal effects — a tool for studying central signaling without the confound of a systemic stress-hormone response.
| Property | Detail |
|---|---|
| Sequence | Met-Glu-His-Phe-Pro-Gly-Pro (MEHFPGP) |
| Length | 7 amino acids (heptapeptide) |
| Molecular formula | C37H51N9O10S |
| Molecular weight | ~813.9 g/mol |
| CAS number | 80714-61-0 |
| PubChem CID | 122178 |
| Parent molecule | ACTH fragment (residues 4–7) + Pro-Gly-Pro tail |
| Structural notes | One methionine (the sulfur in the formula); one histidine; no cysteine, so no disulfide bonds |
| Origin | Institute of Molecular Genetics, Russian Academy of Sciences, 1980s |
| FDA / EMA status | Not approved |
| Russian status | Registered medicine (nasal drops) |
Two analytical details follow from the structure. First, the single methionine is an oxidation site: a +16 Da shift on a mass spectrum is the classic signature of methionine oxidation, and it is one of the first things a reviewer looks for on a Semax certificate of analysis. Second, the histidine imidazole side chain can coordinate metal ions, a property explored in the copper-binding literature on this peptide. Both points are covered further in the quality-control section below.
No single receptor explains the Semax literature, and honest summaries of semax peptide research should say so. The published work clusters around four mechanisms, with very different levels of support.
The most-cited finding in the field comes from Dolotov and colleagues (Brain Research, 2006). In rat experiments, a single administration of Semax raised BDNF protein levels in the hippocampus and basal forebrain, increased expression of the BDNF gene transcript associated with activity-dependent release, and increased expression and activation (tyrosine phosphorylation) of TrkB, the high-affinity BDNF receptor. In other words, Semax did not merely raise the growth factor — it raised the receptor that growth factor signals through, a coordinated upregulation of the whole BDNF–TrkB axis.
Follow-up work extended this to nerve growth factor (NGF). Studies from the same research tradition reported increased NGF expression in the hippocampus alongside BDNF, and work in a rat focal cerebral ischemia model (Dmitrieva, Medvedeva and colleagues) found that both Semax and its PGP fragment altered expression of neurotrophin and neurotrophin-receptor genes — Bdnf, Ngf, Nt-3, TrkB, TrkC and TrkA — in frontoparietal cortex after middle cerebral artery occlusion. That last point is scientifically interesting in its own right: if the three-residue tail alone reproduces part of the gene-expression effect, then some of what is attributed to “Semax” may be pharmacology of its metabolite, a distinction careful study designs need to control for.
Eremin and colleagues (2005) reported that Semax influences dopaminergic and serotonergic systems in rodent brain. In striatal measurements, levels of 5-HIAA — the main serotonin metabolite — rose after Semax administration, and Semax potentiated dopamine release and locomotor effects evoked by D-amphetamine in mice. Researchers read this as neuromodulation rather than direct stimulation: Semax does not appear to act as a classic stimulant, but it changes how monoamine systems respond. The amphetamine-potentiation finding also cuts the other way — it is a flag that interaction effects exist and that abuse-potential questions have not been formally studied.
Kost and colleagues (2001) showed that Semax inhibits enkephalin-degrading enzymes from human serum at micromolar concentrations, a mechanism it shares conceptually with its sister peptide Selank. Longer-lived enkephalins would be expected to modulate pain and stress signaling, though the contribution of this pathway to Semax’s overall profile is unresolved. Semax has also been reported to interact with melanocortin receptors MC4R and MC5R in vitro (including antagonist-like behavior in some assay systems), which is plausible given its ACTH ancestry — but the receptor pharmacology is not settled, and claims that Semax “works through MC4R” go beyond what the binding data support.
Medvedeva and colleagues (2014) took a genome-wide approach, profiling gene expression in rat brain after focal ischemia with and without Semax. Semax altered expression of hundreds of genes, with prominent clusters in immune-response and vascular pathways, in addition to the neurotrophin effects above. Transcriptomic studies of this kind are hypothesis-generating rather than conclusive, but they support the picture of Semax as a broad gene-expression modulator in injured brain tissue rather than a single-target agent.
This is where semax peptide research needs its most careful reading. Semax is registered in Russia, where it has been used clinically — primarily as nasal drops — in contexts including acute ischemic stroke and certain cognitive and optic-nerve disorders, and it was added to Russia’s list of vital and essential medicines. Russian clinical studies from the 1990s and 2000s report outcomes in stroke cohorts, and Russian regulatory acceptance is a real fact about the compound’s history.
But three limitations define the human evidence for outside reviewers:
The accurate summary is: a long history of regulated clinical use in one country, a biologically coherent animal literature, and a human evidence base that has never been independently validated to FDA or EMA standards.
Semax is not an FDA-approved drug, and it is not approved by the EMA. There is no FDA-approved Semax product of any kind.
Its US compounding history follows the pattern now familiar across this peptide class. In September 2023, the FDA placed Semax in Category 2 of the interim Section 503A bulk drug substances list — the category for substances the agency identified as raising significant safety concerns, which cannot be compounded while listed. The nomination underlying its evaluation was later withdrawn, and Semax was among the substances removed from Category 2 in April 2026 — a procedural change that, as the FDA stated, is not an authorization to compound.
On July 23–24, 2026, the FDA’s Pharmacy Compounding Advisory Committee (PCAC) evaluated Semax for the 503A Bulks List, with nominated uses in cerebral ischemia, migraine, and trigeminal neuralgia. The committee voted 8–5, with one abstention, to recommend including Semax (free base) on the Bulks List — against the recommendation of FDA staff reviewers. That vote is advisory only. Semax is not on the 503A Bulks List today, compounding remains unavailable, and any change requires the FDA to accept the recommendation and complete formal rulemaking. None of this process is a drug approval, and none of it endorses the cognitive-enhancement claims attached to the peptide in popular coverage.
For laboratory researchers, the operative status is simpler: in the US, Semax is an RUO material, supplied for in vitro and preclinical laboratory research only.
Semax is routinely confused with Selank, and the comparison is instructive because the two peptides were engineered with the same trick for different targets.
| Semax | Selank | |
|---|---|---|
| Parent fragment | ACTH(4–7) | Tuftsin (Thr-Lys-Pro-Arg) |
| Sequence | Met-Glu-His-Phe-Pro-Gly-Pro | Thr-Lys-Pro-Arg-Pro-Gly-Pro |
| Shared feature | Pro-Gly-Pro C-terminal tail for stability | Pro-Gly-Pro C-terminal tail for stability |
| Primary literature focus | BDNF/TrkB, neuroprotection, ischemia gene expression | GABAergic gene expression, enkephalinase inhibition, immunomodulation |
| Molecular weight | ~813.9 g/mol | ~751.9 g/mol |
| Regulatory parallel | Registered in Russia; not FDA/EMA approved | Registered in Russia (2009); not FDA/EMA approved |
Both are seven residues, both carry the PGP tail, and both came out of the same Moscow peptide-engineering tradition — but their parent fragments point them at entirely different biology, and their literatures should not be merged. Our Selank profile covers the tuftsin side of this family in full.
Because Semax is a small, fully synthetic peptide, its identity and purity are straightforward to verify — and worth verifying, because the failure modes are specific:
Handling follows standard small-peptide practice: store lyophilized material sealed, cold, dry, and protected from light; reconstitute only what an experiment requires; and avoid repeated freeze-thaw cycles, which accelerate the same oxidation and aggregation pathways the COA is designed to detect. Researchers comparing material across suppliers will find the Semax research peptide specification a useful reference point for sequence, form, and documentation.
Is Semax the same as ACTH? No. Semax copies only residues 4–7 of ACTH and adds a synthetic Pro-Gly-Pro tail. It lacks ACTH’s adrenal, cortisol-raising activity, which is precisely why it was designed.
Why does the literature emphasize BDNF so heavily? Because it is the most reproducible molecular finding: Dolotov et al. (2006) showed coordinated increases in BDNF protein, BDNF gene expression, and TrkB expression and activation in rat hippocampus, and later ischemia-model work extended the neurotrophin findings to NGF and the Trk receptor family.
Does Russian registration mean Semax is proven? It means a national regulator accepted it for defined uses on the evidence available to it. It does not substitute for independently replicated, placebo-controlled trials, which do not exist for Semax in the international literature — and it is not FDA or EMA approval.
What did the July 2026 FDA advisory vote change? Nothing immediate. The PCAC recommended (8–5–1) that Semax be considered for the 503A Bulks List against FDA staff advice. Until the FDA acts through rulemaking, Semax cannot be compounded in the US, and the vote has no bearing on its RUO laboratory status.
How is Semax different from other “peps” in the nootropic category? Most compounds grouped under that slang have no regulatory history anywhere. Semax is unusual in having a decades-long registered clinical history in Russia — and equally unusual in how little of its human evidence is accessible to independent review. Both halves of that sentence matter.
Related in the Apex shop: Semax research peptide — supplied strictly for laboratory research use.
Disclaimer: This article is for educational and laboratory research purposes only. Semax supplied by Apex Bio Industries is a research-use-only material, not a drug, dietary supplement, or cosmetic, and is not intended for human or veterinary use, diagnostic use, or therapeutic use. Nothing in this article is medical advice or a claim of safety or efficacy.
Peptide purity vs potency is the most common source of confusion on a research peptide certificate of analysis, and it
SS-31 peptide research occupies a place almost no other research peptide reaches: one form of this four-amino-acid molecule is now
Antimicrobial peptides research starts from a simple observation: almost every living organism makes small peptides that can kill or slow
